Carl Zeiss Meditec
DUBLIN, Calif.--(BUSINESS WIRE)--Carl Zeiss Meditec, a leader in ophthalmic devices and surgical systems,
announced today that two new optical coherence tomography (OCT)
applications will be available for the first time at the American
Society of Cataract and Refractive Surgeons (ASCRS) meeting in Chicago,
IL at booth 2028. With advanced algorithms available for Cirrus™
HD-OCT and Stratus™ OCT, ophthalmologists now
have the most advanced imaging capabilities available for assessing and
managing glaucoma and diseases of the retina.
The Cirrus HD-OCT, the latest addition to the Zeiss OCT family of
products, provides the most detailed scan patterns and layer maps
available for identifying retinal and glaucoma disease characteristics,
and monitoring disease progression. Nearly 1000 Cirrus HD-OCT units have
been sold worldwide since its introduction last November. It is the
first in its category to deliver high-definition 3D maps to spectral
domain technology.
"The Cirrus HD-OCT 3-D images bring us a new level of insight into the
detailed structure of the retina,” said Peter
K. Kaiser, MD, Director of the Clinical Research Center, Cole Eye
Institute in Cleveland. “Combined with the
proprietary image analysis algorithms developed by the veteran Zeiss
team, the Cirrus gives us new volumetric data that expands our ability
to interpret the three dimensional images in a highly reproducible,
quantitative fashion."
For the first time, Stratus OCT features both Advanced Serial Analysis
and Guided Progression Analysis™ (GPA)
software for objective measurement and subjective clinical evaluation in
the detection of glaucoma and retinal diseases. Advanced Serial Analysis
plots RNFL thickness over time and reports statistically significant
change, enabling practitioners to project future vision loss and make
timely treatment decisions.
Stratus OCT is the standard of care system for comprehensive retinal
scanning. With nearly 9,000 Stratus OCT units in use worldwide, more
than 37,000 scans performed each year and backed by over 100 U.S.
clinical studies for retinal disease, the Stratus OCT is the most widely
adopted and researched OCT system in the world.
“From pioneering the first OCT platform nearly
a decade ago to launching the newest Cirrus HD-OCT system late last
year, Zeiss continues its tradition of leadership with spectral domain
technology,” said Jim Taylor, Carl Zeiss
Meditec president and chief executive officer. “The
new features for the Cirrus and Status OCT systems provide efficiencies
that allow physicians to more easily gather and interpret detailed
disease information while streamlining workflow processes that impact
the entire practice. Our ultimate goal is to enable our customers to
provide the best quality of care possible to their patients.”
Optical coherence tomography (OCT) is an imaging method that uses light
to scan the retina, and can be performed on undilated pupils as small as
3 mm in diameter. It provides detailed, real-time information about the
structure of the living eye available to the clinician. Using light to
scan the retina and optic disc, this pioneering technology brought new
clinical tools for the diagnosis and management of retinal disease and
glaucoma.
About Carl Zeiss Meditec
Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world’s
leading medical technology companies. This market position is based on
over 160 years of experience in optical innovation.
The company has two primary areas of activity: In the field of ophthalmology
Carl Zeiss Meditec offers integrated solutions for treating the four
main eye ailments: vision defects (refraction), cataract, glaucoma and
retinal disorders. The company’s system
solutions are employed in all phases of the disease management, from
diagnosis to treatment and aftercare. Carl Zeiss Meditec has always
applied its technological expertise to product innovations. These
innovations range from basic systems such as slit lamps and fundus
cameras to standard setting diagnostic systems such as the Humphrey®
Field Analyzer, the Stratus OCT™ and the
IOLMaster®, through
to the surgical microscopes and innovative treatment systems in
refractive laser surgery. The product portfolio in ophthalmic surgery is
rounded off by intraocular lenses and consumables.
In the field of neuro and ENT surgery, Carl Zeiss Meditec is the
world’s leading provider of surgical
microscopes and microsurgical visualization solutions for a very broad
range of applications, such as tumor and vascular surgery in the head
region and/or spinal surgery. The most recent example of the innovative
performance in the area of microsurgery is the OPMI Pentero®
visualization system, which allows efficient and ergonomic patient
treatment. Carl Zeiss Meditec will systematically expand its product
range in this area and become a solution provider in neuro and ENT
surgery as well.
Carl Zeiss Meditec’s medical technology
portfolio is rounded off by visualization systems for doctors in private
practice and promising future technologies such as intraoperative
radiation therapy, which allows the targeted treatment of breast cancer
and brain cancer directly during surgery.
Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in
Germany (Carl Zeiss Surgical GmbH, Carl Zeiss Meditec
Vertriebsgesellschaft mbH, *Acri.Tec AG and Carl Zeiss Medical Software
GmbH), the USA (Carl Zeiss Meditec, Inc., Dublin), in Japan (Carl Zeiss
Meditec Co., Ltd., Tokyo), Spain (Carl Zeiss Meditec Iberia S.A.,
Madrid) and France (Carl Zeiss Meditec S.A.S., La Rochelle, and Carl
Zeiss Meditec France SAS, Le Pecq).